Theorem Clinical Research

R&D Trends

Roche, Garvan Institute of Medical Research partner

Wednesday, August 20, 2014 01:22 PM

Roche and the Australia-based Garvan Institute of Medical Research are collaborating to develop new technologies for targeted epigenomic analysis using DNA sequencing. Genomics is a rapidly evolving field with a focus on realizing the potential use of sequencing information in patient diagnosis and treatment.

More... »


A*STAR, Sumitomo Mitsui Banking ink MOU for Japanese R&D in Singapore

Wednesday, August 20, 2014 01:19 PM

The Singapore-based Agency for Science, Technology and Research (A*STAR) and Japan-based Sumitomo Mitsui Banking Corporation (SMBC) have inked a memorandum of understanding (MOU), with the aim of supporting Japanese R&D activities in Singapore for the next three years.

More... »


MD Anderson, Foundation Medicine partner

Friday, August 15, 2014 02:52 PM

The University of TexasMD Anderson Cancer Center has announced an alliance with Cambridge, Mass.-based Foundation Medicine. The teams are opening a randomized, controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease.

More... »

Biocryst Pharmaceuticals receives NIAID funds for hemorrhagic fever viruses

Thursday, August 14, 2014 11:44 AM

BioCryst Pharmaceuticals, based in Research Triangle Park, N.C., has announced the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct phase I clinical human safety trials of an intramuscular formulation of BCX4430.

More... »

ZAI Lab, Sanofi ink agreement for chronic respiratory disease compounds

Thursday, August 14, 2014 11:43 AM

ZAI Lab, a biotech company in China, has entered into a global licensing agreement with Sanofi for two novel compounds for the potential treatment of chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF). The compounds were discovered by Sanofi and currently are in preclinical stage.

More... »

U.S. research institutions collaborate to share, standardize neuroscience databases

Wednesday, August 13, 2014 01:04 PM

The Allen Institute for Brain Science based in Seattle, Wash., the California Institute of Technology, the New York University School of Medicine, the Howard Hughes Medical Institute (HHMI) in Massachusetts and the University of California, Berkeley are collaborating on a project aimed at making databases about the brain more useable and accessible for neuroscientists—a step seen as critical to accelerating the pace of discoveries about the brain in health and disease.

More... »

Daiichi Sankyo, Charleston Laboratories collaborate on hydrocodone products for pain

Monday, August 11, 2014 01:45 PM

Daiichi Sankyo and Charleston Laboratories, through its wholly owned subsidiary LOCL Pharma, have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories’ novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of opioid-induced nausea and vomiting (OINV).

More... »

Sanofi licenses Immune Design's GLAAS platform to treat food allergies

Monday, August 11, 2014 01:38 PM

Sanofi and Immune Design, a clinical-stage immunotherapy company, have entered into a licensing agreement for use of Immune Design's GLAAS discovery platform to develop therapeutic agents to treat a selected food allergy.

More... »

Cancer Research U.K., Cancer Research Technology ink agreement with Astellas

Monday, August 11, 2014 01:35 PM

Cancer Research U.K. and its commercial arm, Cancer Research Technology (CRT), have joined with Astellas Pharma to conduct a two-year research program in the U.K. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

More... »

Igenica Biotherapeutics awarded SBIR grant for antibody drug conjugate technology

Friday, August 8, 2014 01:09 PM

Igenica Biotherapeutics, focused on the discovery and development of innovative cancer antibody-drug conjugates (ADCs), has been awarded a $215,740 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support continued development of its SNAP site-specific ADC linker technology.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs